PMID- 12065090
OWN - NLM
STAT- MEDLINE
DCOM- 20020925
LR  - 20190720
IS  - 0304-3835 (Print)
IS  - 0304-3835 (Linking)
VI  - 183
IP  - 2
DP  - 2002 Sep 26
TI  - Recombinant arginine deiminase as a potential anti-angiogenic agent.
PG  - 155-62
AB  - Arginine deiminase (ADI), isolated from Mycoplasma cell extracts, has been 
      suggested to inhibit endothelial cell growth in vitro. However, anti-angiogenic 
      activity by ADI has not yet been demonstrated. In this study, we investigated the 
      in vitro effect of recombinant ADI (rADI) on the growth, migration, and tube 
      formation of human umbilical vein endothelial (HUVE) cells. Mycoplasma arginine 
      deiminase was cloned by PCR and the rADI was expressed in Escherichia coli. and 
      purified to near homogeneity. The purified recombinant protein was found to have 
      characteristics similar to those of the native enzyme: molecular weight (48 kDa) 
      and specific enzymatic activity of converting L-arginine into citrulline (32.7 
      U/mg). This recombinant enzyme also exhibited an inhibitory effect on the growth 
      of HUVE cells. The anti-angiogenic activity was demonstrated by in vitro 
      inhibition of migration into the scratch wounded area in HUVE cell monolayers and 
      the inhibition of microvessel tube-like formation of HUVE cells on 
      Matrigel-coated surfaces. These results suggest that arginine deiminase is a 
      potential inhibitor for angiogenesis, and that arginine concentrations may play 
      an important role in regulating neovascularization.
FAU - Beloussow, Karin
AU  - Beloussow K
AD  - Department of Pharmaceutical Sciences, University of Southern California School 
      of Pharmacy, PSC 404B, 1985 Zonal Avenue, Los Angeles, CA 90089-9121, USA.
FAU - Wang, Li
AU  - Wang L
FAU - Wu, Jun
AU  - Wu J
FAU - Ann, David
AU  - Ann D
FAU - Shen, Wei Chiang
AU  - Shen WC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - 29VT07BGDA (Citrulline)
RN  - 94ZLA3W45F (Arginine)
RN  - EC 3.- (Hydrolases)
RN  - EC 3.5.3.6 (arginine deiminase)
SB  - IM
MH  - Angiogenesis Inhibitors/*pharmacology
MH  - Arginine/pharmacology
MH  - Cell Division
MH  - Cell Movement
MH  - Cells, Cultured
MH  - Citrulline/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Endothelium, Vascular/cytology
MH  - Escherichia coli/metabolism
MH  - Humans
MH  - Hydrolases/*pharmacology
MH  - Microcirculation/pathology
MH  - Mutagenesis, Site-Directed
MH  - Mycoplasma/metabolism
MH  - Recombinant Proteins/metabolism/*pharmacology
MH  - Umbilical Veins/cytology
EDAT- 2002/06/18 10:00
MHDA- 2002/09/26 06:00
CRDT- 2002/06/18 10:00
PHST- 2002/06/18 10:00 [pubmed]
PHST- 2002/09/26 06:00 [medline]
PHST- 2002/06/18 10:00 [entrez]
AID - S0304383501007935 [pii]
AID - 10.1016/s0304-3835(01)00793-5 [doi]
PST - ppublish
SO  - Cancer Lett. 2002 Sep 26;183(2):155-62. doi: 10.1016/s0304-3835(01)00793-5.